Users Stopping Slimming Medications Regain Weight Four Times Faster Compared to Those on Conventional Diets

Fresh analysis suggests that people who stop using new weight-loss injections like semaglutide or tirzepatide may regain shed pounds far faster than those who halt traditional lifestyle plans.

Findings released in a prominent health publication shows that while obese people often shed about a fifth of their total mass while undergoing treatment, the mass is regained at an average rate of nearly a kilo each month upon discontinuation.

"Individuals using these treatments should be aware of the danger of rapid rebound weight gain when the medication ends," cautioned lead investigator Dr. Susan Jebb.

Such speed of recovery means a return to starting mass in about a year and a half.

Weighing Approaches

The study, which examined dozens of trials involving thousands of participants, compared the results of GLP-1 agonists with conventional dieting.

The team note that individuals who lose weight through lifestyle changes alone usually experience a more gradual creep back—perhaps 0.1 kg a month—once they finish.

The Reason for the Fast Rebound

Doctors propose the mode of action of the drugs is key to understanding the amplified rebound.

The injections copy a natural hormone called glucagon-like peptide-1, which helps regulate feelings of fullness.

"Artificially providing GLP-1 concentrations several times higher than normal may cause the system to generate a reduced amount of its endogenous GLP-1, and may also diminish responsiveness to its actions," noted Dr. Adam Collins, a nutrition specialist.

"Stopping of this medication results in appetite is unsuppressed, making overeating a significant risk."

An Ongoing Condition?

The NHS recommend the injections for people with weight-linked medical conditions, accompanied by recommended diet and exercise modifications.

A number of clinicians say that, considering the significant potential of weight regain, the treatment is often long-term.

This perspective is echoed by pharmaceutical companies, who note that the results "highlight the persistent nature of obesity," comparing it to managing diseases like high blood pressure.

User Accounts

Users who have come off the jabs report a powerful return of cravings.

"I experienced a trigger flipping and you're instantly ravenous," described one woman.

The struggle is compounded if users have not developed lasting dietary or behavioural changes during therapy.

Significant Use

Figures indicate that a significant number of people in the UK have tried weight-loss jabs in the last 12 months, with interest continuing to grow.

• Use is higher among females compared to males.
• The 40s and 50s age group shows the greatest usage rates.
• A large proportion obtain the drugs through private healthcare rather than public health services.

Finally, clinicians emphasize that while these medications are effective tools for shedding pounds, they are not a standalone cure and lasting health benefits likely depends on combined behavioural changes.